Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22%
Novo Nordisk raised its 2026 sales and operating-profit outlook after strong demand for obesity drugs helped it beat third-quarter expectations. Obesity-care sales grew 22%, though reported operating profit fell because of impairment… charges. The company also projected higher free cash flow and announced planned U.S. price cuts for Wegovy and Ozempic starting in 2027.